Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

NCT03132636

CompletedPhase 2

Sponsor: Regeneron Pharmaceuticals

Conditions: Carcinoma, Basal Cell

Interventions: cemiplimab

Countries: United States, Austria, Belgium, Canada, France, Germany, Greece, Italy

The primary objective is to estimate the objective response rate (ORR) for metastatic Basal Cell Carcinoma (BCC) (group 1) and for unresectable locally advanced BCC (group 2) when treated with cemiplimab as a monotherapy

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Key Inclusion Criteria:

* Confirmed diagnosis of invasive BCC
* Progression of disease on hedgehog inhibitor (HHI) therapy or intolerance of prior HHI therapy
* At least 1 measurable lesion
* ≥18 years of age
* Hepatic function, renal function, bone marrow function in defined lab-value-ranges
* Anticipated life expectancy \>12 weeks
* Consent to provide archived tumor biopsy material (all patients)
* Group 2: consent to undergo research biopsies
* Group 2: must not be a candidate for radiation therapy or surgery
* Comply with study procedures and site visits
* Sign Subject Information Sheet and Informed Consent Form

Key Exclusion Criteria:

* Ongoing or recent significant autoimmune disease
* Prior treatment with specific pathway-blockers (PD-1/PD-L1)
* Prior treatment with immune-modulating agents within 28 days before cemiplimab
* Untreated brain metastasis that may be considered active
* Immunosuppressive corticosteroid doses (\>10mg prednisone) within 28 days prior to treatment with cemiplimab
* Active infections requiring therapy, including HIV, hepatitis
* Pneumonitis within the last 5 years
* Cancer treatment other than radiation therapy, including investigational or standard of care, within 30 days prior to treatment with cemiplimab
* Documented allergic reactions or similar to antibody treatments
* Concurrent malignancies other than BCC, other than those with negligible risk of metastases or death
* Any acute or chronic psychiatric problems
* Having received a solid organ transplantation
* Inability to undergo contrast radiological assessments
* Breastfeeding, pregnant, women of childbearing potential not using contraception

Note: Other protocol-defined inclusion/exclusion criteria apply
Locations (71)
  • Phoenix, Arizona, United States
  • Phoenix, Arizona, United States
  • La Jolla, California, United States
  • Redwood City, California, United States
  • San Francisco, California, United States
  • Denver, Colorado, United States
  • Miami, Florida, United States
  • Tampa, Florida, United States
  • Chicago, Illinois, United States
  • Louisville, Kentucky, United States
  • Boston, Massachusetts, United States
  • Boston, Massachusetts, United States
  • St Louis, Missouri, United States
  • Morristown, New Jersey, United States
  • Summit, New Jersey, United States
  • New York, New York, United States
  • New York, New York, United States
  • New York, New York, United States
  • Columbus, Ohio, United States
  • Hershey, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Houston, Texas, United States
  • Salt Lake City, Utah, United States
  • Graz, Styria, Austria
  • Innsbruck, Austria
  • Brussels, Belgium
  • Leuven, Belgium
  • Edmonton, Alberta, Canada
  • Toronto, Ontario, Canada
  • Toronto, Ontario, Canada
  • + 41 more on CT.gov